Cost effectiveness of screening for Chlamydia trachomatis: A review of published studies

Sexually Transmitted Infections

Volumn 78, Issue 6, 2002, Pages 406-412

  Honey, E ^a   Augood, C ^b   Templeton, Allan ^a   Russell, I ^c   Paavonen, J ^d   Mardh P A ^e   Stary, A ^f   Stray Pedersen, B ^g  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d UNIVERSITY OF HELSINKI   (Finland)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f Out patient Center   (Austria)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BIBLIOGRAPHIC DATABASE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DNA DETERMINATION; ECONOMIC EVALUATION; FEMALE; GENITAL TRACT INFECTION; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; OUTCOMES RESEARCH; PELVIC INFLAMMATORY DISEASE; POPULATION RESEARCH; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITATIVE DIAGNOSIS; REVIEW; SCREENING TEST; SEXUAL BEHAVIOR; STATISTICAL MODEL;

CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MASS SCREENING; RANDOMIZED CONTROLLED TRIALS;

EID: 0036913180     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.78.6.406     Document Type: Review

References (36)

1. Taylor-Robinson D. Chlamydia trachomatis and sexually transmitted disease. BMJ 1994;308:150-1.
2. Cates WJ, Wasserheit JN. Genital chlamydial infections:Epidemiology and reproductive sequelae. Am J Obstet Gynecol 1991;164:1771-81.
3. Svensson L, Mardh PA, Westrom L. Infertility after acute salpingitis with special reference to Chlamydia trachomatis. Fertil Steril 1983;40:322-39.
4. Westrom L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol 1980;138:880-92.
5. Department of Health. Why mothers die. Report on the Confidential Enquiries into Maternal Deaths in the United Kingdom 1994-1996. London: HMSO, 1998.
6. Svensson LO, Mares I, Mardh P-A, et al. Screening voided urine for Chlamydia trachomatis in asymptomatic adolescent females. Acta Obstet Gynecol Scand 1994;73:63-66
7. Tchoudomirova K, Nuhova P, Tchapanova A. Prevalence, epidemiological and clinical correlates of genital Chlamydia trachomatis infection. J Eur Acad Dermatol Venereol 1998;11:214-20.
8. Ripa T. Epidemiologic control of genital Chlamydia trachomatis infections. Scand J Infect Dis Suppl 1990;69:157-67.
9. Gaydos CA, Howell MR, Pare, B et al. Chlamydia trachomatis infections in female military recruits. N Engl J Med 1998;339:739-44.
10. CMO. Expert Advisory Group. Chlamydia Trachomatis - Summary and Conclusions of Chief Medical Officer's Group. London: Department of Health, 1998:1-22.
11. Paavonen J, Lehtinen M. Chlamydial pelvic inflammatory disease. Human Reproduction Update 1996;2:519-29.
12. Egger M, Low N, Smith GD, et al. Screening for chlamydial infections and the risk of ectopic pregnancy in a county in Sweden: Ecological analysis. BMJ 1998;316:1776-80.
13. Scholes D, Stergachis A, Heidrich FE, et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996;334:1362-6.
14. Donaldson C, Shackley P. Economic evaluation. In: Detels R, Holland W, McEwan J, Omenn F, eds. Oxford Textbook of Public Health. 3rd Ed. Oxford: Oxford University Press, 1995;26:849-71.
15. Buhaug H, Skjeldestad FE, Halvorsen LE, et al. Should asymptomatic patients be tested for Chlamydia trachomatis in general practice? Br J Gen Pract 1990;40:142-5.
16. Humphreys JT, Henneberry JF, Rickard RS, et al. Cost-benefit analysis of selective screening criteria for Chlamydia trachomatis infection in women attending Colorado family planning clinics. Sex Transm Dis 1992;19:47-53.
17. Sellors JW, Pickard L, Gafni A, et al. Effectiveness and efficiency of selective vs universal screening for chlamydial infection in sexually active young women. Arch Intern Med 1992;152:1837-44.
18. Genc M, Mardh AA. A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women. Ann Intern Med 1996;124:1-7.
19. Marrazzo JM, Celum CL, Hillis SD, et al. Performance and cost-effectiveness of selective screening criteria for Chlamydia trachomatis infection in women. Implications for a national Chlamydia control strategy. Sex Transm Dis 1997;24:131-41.
20. Cohen DA, Nsuami M, Etame RB, et al. A school-based Chlamydia control program using DNA amplification technology. Pediatrics 1998;101:E1.
21. Paavonen J, Puolakkainen M, Paukku M, et al. Cost-benefit analysis of first-void urine Chlamydia trachomatis screening program. Obstet Gynecol 1998;92:292-8.
22. Howell MR, Quinn TC, Brathwaite W, et al. Screening women for chlamydia trachomatis in family planning clinics:The cost-effectiveness of DNA amplification assays. Sex Transm Dis 1998;25:108-17.
23. Howell MR, Quinn TC, Gaydos,CA. Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics. A cost-effectiveness analysis of three strategies. Ann Intern Med 1998;128:277-84.
24. Howell, MR, Gaydos, JC, McKee KTJ, et al. Control of Chlamydia trachomatis infections in female army recruits:Cost-effective screening and treatment in training cohorts to prevent pelvic inflammatory disease. Sex Transm Dis 1999;26:519-26.
25. Drummond M, Stoddart G, Torrance G. Critical assessment of economic evaluation. In: Drummond M, Stoddart G, Tarrance G, eds. Methods for the Economic Evaluation of Health Care Programmes. 1st Ed. Oxford: Oxford Medical Publications 1987;3:18-38.
26. Greenhalgh T. How to read a paper. Papers that tell you what things cost (economic analyses). BMJ 1997;315:596-9.
27. Udvarhelyi IS. Cost. effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly? Ann Intern Med 1992;116:238-44.
28. Keenan SP, Massel D, Inman KJ, et al. A systematic review of the cost-effectiveness of noncardiac transitional care units. Chest 1998;113:172-7.
29. Economic analysis of health care technology. A report on principles. Task Force on Principles for Economic Analysis of Health Care Technology. Ann Intern Med 1995;123:61-70.
30. Grimes DA, Atkins D. The US Preventative Task Force: Putting evidence based medicine to work. Clin Obstet Gynecol 1998;41:332-42.
31. Welte R, Kretzschmar M, Leidl R, et al. Cost effectiveness for screening programmes for Chlamydia trachomatis. Sex Transm Dis 2000;27:518-29.
32. Lee HH, Chernesky MA, Schachter J, et al. Diagnosis of Chlamydia trachomatis genitourinary infection in women by ligase chain reaction assay of urine. Lancet 1995;345:213-16.
33. McIntosh E, Donaldson C, Ryan M. Recent advances in the methods of cost-benefit analysis in healthcare matching the art to the science. Pharmacoeconomics 1999;15:357-67.
34. Stephenson JM. Screening for genital chlamydial infection. Br Med Bull 1998;54:891-902.
35. Grun L, Tassano-Smith J, Carder C, et al. Comparison of two methods of screening for genital chlamydial infection in women attending in general practice:Cross sectional survey. BMJ 1997;315:226-30.
36. Kamwendo F, Forslin L, Bodin L, et al. Programmes to reduce pelvic inflammatory disease - The Swedish experience. Lancet 1998;351:25-8.